Lebwohl, M., Strober, B., Linaberry, M., Hoyt, K., Banerjee, S., Kisa, R. M., & Mehta, N. N. (2023). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine, 7(2), s115. https://doi.org/10.25251/skin.7.supp.115